AbbVie Defends Humira With Aggressive Discount In First EU Tender

AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.

Brown bear
AbbVie has laid down its defense of Humira's European market • Source: Shutterstock

AbbVie Inc. is ready for a fight to keep rivals away from having their piece of the biosimilar adalimumab market if reports of a price cut of 80% are anything to go by.

The discount in an, as yet, unknown market, is not expected to hurt AbbVie much financially. Even with the 80%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Deal Watch: AstraZeneca Remains Busy In AI, Via Deals With Immunai, Turbine And Algen

 

Plus deals involving Takeda/Innovent, Genentech/Ventus, Sanofi/EVOQ, Novo Nordisk/Sumitomo, Lisata/Catalent, Boehringer Ingelheim/Accent, BI/Molcure, tech transfer agreements and more.

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By 

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

How To Score A Win With Real-World Evidence In India

 
• By 

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By 

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

More from Business

Industry Excellence Celebrated At Citeline Japan Awards

 
• By 

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

China’s Next Wave Is First-In-Class Innovation

 

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By 

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.